HUMA.US Humacyte Inc

Healthcare Biotechnology USA Stocks
0.5584 USD
Close of Nov 15, 2026
0.3370 1.53
Market cap
USD 155M
P/E
-
P/B
8.59x
ROE
-516.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HUMA.US undervalued?

Graham number

The Graham number of Humacyte Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Humacyte Inc fundamental analysis

No fundamental analysis for Humacyte Inc yet.

Humacyte Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Humacyte Inc

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to …

Full company profile